Activity Overview
This online, on-demand virtual symposium brings together renowned experts in breast cancer. In this educational program, these experts provide guidance on integrating and sequencing HER2- and TROP2-directed antibody-drug conjugate (ADC) therapies to optimize patient selection and improve outcomes across early and advanced breast cancer settings.
This educational activity is an archive of the live symposium held on March 6, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, pathologists, advanced practice providers, nurses, pharmacists, and other healthcare practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial evidence supporting TROP2- and HER2-directed ADCs for appropriate integration into metastatic breast cancer management
- Develop individualized treatment sequences incorporating TROP2- and HER2-directed ADC therapies based on biomarker and patient characteristics
- Implement multidisciplinary protocols to monitor and manage adverse events
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics
Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Consulting or Advisory Role: BioNTech, Bristol Myers Squibb, Helsinn, Napo; Institutional research funding to prior institution, UCSF: Ambryx, AstraZeneca, Daiichi Sankyo, Inc., F. Hoffman-La Roche/Genentech, Gilead Sciences, Inc., Lilly, Merck & Co, Novartis Pharmaceuticals, Pfizer, Stemline Therapeutics; Institution research funding to current institution, City of Hope: Bicycle Therapeutics, F. Hoffman-La Roche/Genentech, Merck & Co, Stemline Therapeutics
Paolo Tarantino, MD, PhD
Clinical Fellow
Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Menarini/Stemline, Novartis, Roche; Grant/Research Funding: AstraZeneca
Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS
Olga Keith Wiess Chair of Surgery
Professor and Chief, Section of Breast Surgery
Co-director, Lester and Sue Smith Breast Center
Leader, Breast Cancer Program
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Disclosures: Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS, has no relevant financial relationships with ineligible companies.
Giuseppe Curigliano, MD, PhD
Professor of Medical Oncology
University of Milan
Director, Early Drug Development Division
European Institute of Oncology
Milan, Italy
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, BioNTech, Daiichi Sankyo, Exact Sciences, Lilly, Menarini, Merck, Novartis, Pfizer, Roche
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.